Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cancer Research UK picks Jones to replace Lane

This article was originally published in Scrip

Executive Summary

Cancer Research UK has appointed Professor Nic Jones Chief Scientist as from 1 February 2011. Professor Jones, currently Director of Cancer Research UK's Paterson Institute within the University of Manchester, is succeeding Professor Sir David Lane, who is currently leading a pioneering research team in Singapore and will continue to advise the charity on its research strategy as an ongoing member of its scientific strategy advisory group. Professor Jones will step down as the Paterson Institute's Director but will continue to lead his research group at the Paterson which studies how cells respond to sudden adverse changes in their surroundings, known as 'environmental stress'. He will also continue in his role as Director of the Manchester Cancer Research Centre

You may also be interested in...



AI Firm Healx Raises $56M To Develop Affordable Rare Disease Treatments

Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.

Abalos Raises €12M Series A To Develop Arenavirus-Based Cancer Therapies

Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.

Despite BMS Bid, Celgene Pays $75m Upfront For Immatics Assets Options

Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.

Topics

UsernamePublicRestriction

Register

SC011162

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel